PharmAthene, Inc.
http://www.pharmathene.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PharmAthene, Inc.
2Seventy Cuts Jobs As It Streamlines Pipeline, Focuses On Abecma
Nearly two years after its spin-out from bluebird, 2Seventy is slowing in-house R&D and leaning on partners to conserve cash while BMS-partnered Abecma regains its competitive footing.
Generic Hetlioz Does Not Require Braille Labeling, FDA Tells Vanda
FDA says Teva and Apotex’s generic products do not violate the ‘same labeling’ requirement because they were produced by different manufacturers and that braille is not necessary for safe and effective use of tasimelteon products. Vanda's generic labeling suit against the FDA remains pending.
Generic Hetlioz Does Not Require Braille Labeling, FDA Tells Vanda
FDA says Teva and Apotex’s generic products do not violate the ‘same labeling’ requirement because they were produced by different manufacturers and that braille is not necessary for safe and effective use of tasimelteon products. Vanda's generic labeling suit against the FDA remains pending.
Finance Watch: Q2 Saw Fewer, But Larger, Venture Capital Deals
Private Company Edition: Fewer biotech companies raised venture capital in the second quarter, but the amount of capital raised was on par with the first quarter. Also, former BMS R&D exec Rupert Vessey joined Flagship Pioneering, two new VC funds emerged and Septerna raised a $150m series B round.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice